Research statistics
Tabimorelin research: publications and trials
At a glance
Publications, all years
18
Since 1999
Publications in 2026 so far
0
Through November 15, 2026
Human clinical research
33.3%
6 of 18 classified
Registered clinical trials
0
ClinicalTrials.gov
Randomized controlled trials
5
Publications reporting an RCT in people
Systematic reviews and meta-analyses
0
Preclinical studies
61.1%
11 animal · 0 in vitro · 0 computational
Records that only mention it
1
Not counted above
Status in the library: In clinical trials. Groups: Growth hormone axis.
What to keep in mind
- Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
- Not a peptide: it is shown for completeness and left out of every peptide total.
Publications by year
Tabimorelin publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Total |
|---|---|---|---|---|
| 1999 | 0 | 2 | 0 | 2 |
| 2000 | 2 | 2 | 0 | 4 |
| 2001 | 2 | 3 | 0 | 5 |
| 2002 | 0 | 1 | 0 | 1 |
| 2003 | 2 | 1 | 0 | 3 |
| 2004 | 0 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 0 | 1 |
Study types
| Animal study | 11 |
|---|---|
| Randomized controlled trial | 5 |
| Other clinical trial | 1 |
| Review | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Endocrinology | 9 |
|---|---|
| Metabolic health | 4 |
| Gastrointestinal | 1 |
| Neurological and mental health | 1 |
| Obesity and weight management | 1 |
| Reproductive and sexual health | 1 |
Registered clinical trials
A registration is not a result.
No registered trials.
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency.
Clinical endocrinology · May 1, 2003 · Randomized controlled trial · cited 24 times
PMID 12699438 · DOI 10.1046/j.1365-2265.2003.01754.x · Human clinical research
- The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · February 1, 2001 · Randomized controlled trial · cited 14 times
PMID 11437473 · DOI 10.1054/ghir.2000.0188 · Human clinical research
- Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers.
Journal of clinical pharmacology · February 1, 2001 · Randomized controlled trial · cited 12 times · open access
PMID 11210396 · DOI 10.1177/00912700122009971 · Human clinical research
- Evaluation of the conformity of human growth hormone concentrations measured with the DPC Immulite and the Nichols Advantage assays.
Clinical chemistry and laboratory medicine · August 1, 2000 · Randomized controlled trial · cited 0 times
PMID 11071076 · DOI 10.1515/cclm.2000.114 · Human clinical research
- The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · August 1, 2000 · Randomized controlled trial · cited 19 times
PMID 11032702 · DOI 10.1054/ghir.2000.0152 · Human clinical research
- A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.
European journal of clinical pharmacology · February 6, 2003 · Other clinical trial · cited 16 times
PMID 12610745 · DOI 10.1007/s00228-002-0539-1 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Pharmacological characterisation of a new oral GH secretagogue, NN703.
European journal of endocrinology · August 1, 1999 · Animal study · cited 62 times
PMID 10427162 · DOI 10.1530/eje.0.1410180 · Animal studies
- Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency.
Clinical endocrinology · May 1, 2003 · Randomized controlled trial · cited 24 times
PMID 12699438 · DOI 10.1046/j.1365-2265.2003.01754.x · Human clinical research
- The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · August 1, 2000 · Randomized controlled trial · cited 19 times
PMID 11032702 · DOI 10.1054/ghir.2000.0152 · Human clinical research
- A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.
European journal of clinical pharmacology · February 6, 2003 · Other clinical trial · cited 16 times
PMID 12610745 · DOI 10.1007/s00228-002-0539-1 · Human clinical research
- Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal.
European journal of medicinal chemistry · May 1, 2000 · Animal study · cited 15 times
PMID 10889328 · DOI 10.1016/s0223-5234(00)00146-x · Animal studies
Latest publications
- Comprehensive insights into the formation of metabolites of the ghrelin mimetics capromorelin, macimorelin and tabimorelin as potential markers for doping control purposes.
Biomedical chromatography : BMC · February 2, 2021 · Animal study · cited 8 times · open access
PMID 33458843 · DOI 10.1002/bmc.5075 · Animal studies
- [Ghrelin-related drugs: clinical perspectives].
Nihon rinsho. Japanese journal of clinical medicine · September 1, 2004 · Review · cited 0 times
PMID 15506422 · Reviews and meta-analyses
- Adipogenic and orexigenic effects of the ghrelin-receptor ligand tabimorelin are diminished in leptin-signalling-deficient ZDF rats.
European journal of endocrinology · June 1, 2004 · Animal study · cited 8 times
PMID 15191361 · DOI 10.1530/eje.0.1500893 · Animal studies
- Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency.
Clinical endocrinology · May 1, 2003 · Randomized controlled trial · cited 24 times
PMID 12699438 · DOI 10.1046/j.1365-2265.2003.01754.x · Human clinical research
- A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.
European journal of clinical pharmacology · February 6, 2003 · Other clinical trial · cited 16 times
PMID 12610745 · DOI 10.1007/s00228-002-0539-1 · Human clinical research
- Absorption and systemic availability of two synthetic growth hormone secretogogues and transport of glucose by the proximal small intestine of anestrus dogs after administering estradiol.
Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology · January 9, 2003 · Animal study · cited 2 times
PMID 12592444 · DOI 10.1007/s00360-002-0312-x · Animal studies
- The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency.
European journal of medicinal chemistry · June 1, 2002 · Animal study · cited 9 times
PMID 12204475 · DOI 10.1016/s0223-5234(02)01370-3 · Animal studies
- Daily low-dose administration of growth hormone secretagogue stimulates pulsatile growth hormone secretion and elevates plasma insulin-like growth factor-1 levels in pigs.
Endocrine · December 1, 2001 · Animal study · cited 8 times
PMID 11954663 · DOI 10.1385/endo:16:3:195 · Animal studies
- Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin.
Bioorganic & medicinal chemistry letters · July 1, 2001 · Animal study · cited 9 times
PMID 11459660 · DOI 10.1016/s0960-894x(01)00345-6 · Animal studies
- The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · February 1, 2001 · Randomized controlled trial · cited 14 times
PMID 11437473 · DOI 10.1054/ghir.2000.0188 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: NN703; Tabimorelin
((TITLE_ABS:"NN703" OR CHEM:"NN703" OR TITLE_ABS:"NN 703" OR CHEM:"NN 703") OR (TITLE_ABS:"Tabimorelin" OR CHEM:"Tabimorelin")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Tabimorelin research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/tabimorelin